Effects of age on noninvasive assessments of vascular function in nonhuman primates: implications for translational drug discovery by Delvin R Knight et al.
Knight et al. Journal of Translational Medicine 2013, 11:101
http://www.translational-medicine.com/content/11/1/101RESEARCH Open AccessEffects of age on noninvasive assessments of
vascular function in nonhuman primates:
implications for translational drug discovery
Delvin R Knight Jr, Andrew H Smith, Richard L Schroeder, Chunli Huang, David A Beebe, Sharon A Sokolowski
and Miao Wang*Abstract
Background: Endothelium-dependent flow mediated dilation (FMD) and pulse-wave velocity (PWV), are used as
measures of vascular health and predictors of cardiovascular risk in clinical studies, and both are age-dependent.
Numbers of circulating endothelial microparticles (EMPs) and endothelial progenitor cells (EPCs) are also associated
with cardiovascular risk, but independent of age in humans. The use of these measurements for pre-clinical
assessment of drug cardiovascular safety and efficacy in non-human primates (NHPs) may promote the translation
of drug-induced effects on vascular function to clinic outcomes. However, in NHPs, the age effects on the
non-invasive measurements of FMD and PWV and the relationship of EMPs/EPCs with FMD are unknown.
Methods: A non-invasive, clinically-relevant approach to assess FMD and PWV was used to examine their
relationship with age and with EMPs/EPCs in NHPs. The effects on FMD of nicotine and rosiglitazone were
evaluated in senescent primates in an effort to validate our FMD method for pre-clinical assessment of vascular
function.
Results: FMD and PWV methods were established in a colony (n = 25) of metabolically healthy, cynomolgus monkeys
ranging in age from 6 to 26 years. FMD, defined as the percent change, at 1 min of cuff release, from baseline vascular
diameter (0.15 ± 0.03 cm), had a strong, negative correlation with age (r = -0.892, p < 0.0001), ranging from 6% to 33%.
PWV positively correlated with age (r = 0.622, p < 0.002) in the same healthy monkeys. Nicotine and rosiglitazone, were
evaluated in subsets of senescent primates (mean age 16.3 ± 1.5[SEM] years). Rosiglitazone significantly improved FMD
(21.0 ± 1.6% vs. vehicle 16.3 ± 1.6%, p < 0.01) without changing baseline diameters, and coincided with a significant
increase in circulating numbers of endothelial progenitor cells (CD45-CD31 + CD34 + VEGFR2+ 7.1 ± 1.3 vs. 4.8 ± 1.1
counts/μl) and a decrease in endothelial microparticles (CD45-CD42a-CD54+ 26.7 ± 11.1 vs. 62.2 ± 9.8 counts/μl)
(p < 0.05). Conversely, FMD was significantly reduced with nicotine (8.7 ± 1.4% vs. vehicle 20.1 ± 2.2%, p < 0.05).
Conclusions: Adult NHPs demonstrate the characteristic linear relationship between age and vascular function using
the non-invasive clinically-related measurements of FMD and PWV. However, numbers of circulating EMPs and EPCs did
not correlate with age. Endothelial function assessed with FMD, together with EMPs/EPCs assessment, may serve as a
novel approach for translational research and therapeutic discovery. Age should be considered in the study design or
data analyses when FMD or PWV is used in NHPs.
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Clinically, vascular function may be evaluated non-
invasively by measuring flow mediated vascular dilation
(FMD) [1], which assesses endothelial function as arter-
ial vasodilation induced by an increase in luminal blood
flow, and pulse wave velocity (PWV), which measures
arterial stiffness as the velocity of pressure pulse waves
through the aorta [2]. Both endothelial dysfunction and
aortic stiffness are associated with diseases and conven-
tional cardiovascular risk factors [1-6]. FMD and PWV
are also predictors of cardiovascular events in humans
[7,8]. Aging is associated with both functional and
structural changes in the vasculature [9], and leads to
impaired FMD [6] and increased PWV [3,10]. When
assessing vascular function during interventional drug
trials [11,12], age is a classic confounding factor.
Non-human primate (NHP) is an important transla-
tional preclinical model for cardiovascular disease, dia-
betes and other metabolic diseases [13-16] and like
humans can naturally develop glucose intolerance and dia-
betes without pharmacological or surgical inducement
[16,17]. FMD and PWV have been used to evaluate test
drugs and disease effects [16,18] in NHPs. However, the
age effects on these measures of vascular function (FMD
and PWV), which are well-documented in humans, re-
main unaddressed in NHPs. Since NHP can live as adults
for decades, a better understanding of the relationship be-
tween age and FMD/PWV would be important in order to
avoid the confounding effects of age when interpreting
FMD and PWV [18].
Thus, our primary goal was to develop the methods to
measure FMD and PWV in NHPs and to examine the
effects of age on these clinically relevant assessments of
vascular function. In addition, we explored using FMD
in senescent NHPs as a translational approach to cardio-
vascular efficacy/safety assessment. Here, we focus on
FMD because there is limited information on using
PWV for clinical assessment of drug effects, and FMD
has emerged as an important clinical measurement for
assessing cardiovascular risk factors and disease the-
rapies [5,11,19]. For example, chronic treatment with
rosiglitazone improve FMD from ~5% to ~7% in patients
with type 2 diabetes mellitus [11]. To make the efficacy/
safety assessment, rosiglitazone, which targets PPARγ
nuclear receptor, was used to show beneficial vascular
effects, and nicotine was used to mimic the well-known
detrimental effects of smoking on FMD. Finally, endo-
thelial microparticles (EMPs, membrane coated vesicles)
and endothelial progenitor cells (EPCs, a population of
cells in the blood involved in endothelial repair), are
associated with cardiovascular risk in humans [20,21]
and are being investigated as clinical biomarkers of
endothelial vascular health. Here, we have a unique op-
portunity to examine the relationship of EPCs/EMPswith age and FMD by addressing these “clinically rele-
vant” biomarkers in our primate model. Since PPARγ
improves endothelial functions [22,23] and increases the
numbers of EPCs [24,25], we determined the effects of




Studies were conducted with the approval of the Pfizer
Institutional Animal Care and Use Committee. Twenty-
five healthy monkeys (Macaca fascicularis, also known
as cynomolgus) (aged at 6 to 26 years, 18 males and 7
females) were studied. These monkeys were paired
housed, when appropriate, in a room with temperature
of 19-25°C, humidity of 30-70%, and 12:45/11:15 light/
dark cycles with a 45 minute ramping period to full
lights on/off as simulated dawn/dusk. The monkeys were
fed a primate chow diet (PMI Certified Hi Fiber Primate
Diet, LabDiet 5K91, PMI Nutrition International, St.
Louis, MO) supplemented with fruits and/or vegetables
with the amount adjusted to maintain a normal body
weight. Conscious primates, previously conditioned to
chair restraint (Plas-Labs, Inc. Lansing, MI), were seated
comfortably in a primate chair for drug administration
and blood collection prior to vascular measurements.
Measurement of artery flow mediated dilation (FMD) and
pulse-wave velocity (PWV)
We established clinically-relevant, non-invasive me-
thods to examine FMD and PWV in non-human primates
(Figure 1). FMD and PWV were measured between 9 am
to 12:30 pm on overnight fasted monkeys. Monkeys were
sedated with butorphanol (0.3 mg/kg, im) and midazolam
(0.5 mg/kg, im), or with ketamine (5 mg/kg, im) +
midazolam (0.35 mg/kg, im), placed on a 37°C heating
pad to maintain body temperature, oriented in a right lat-
eral recumbent position to allow access the right brachial
and femoral arteries. Stable mean arterial blood pressure
and heart rate during these procedures averaged 79
mmHg and 142 beats/min, respectively.
Electrocardiography (ECG) electrodes were placed, to
collect a lead II ECG signal. Pulse waves from the brachial
and femoral arteries, were recorded using a SphygmoCor
(AtCor, Itasca, IL) PWV probe that was associated with a
modified SphygmoCor program (CvMSV9; modified for
high rates). Distal-proximal distances were measured and
entered into the program. PWV was calculated by the pro-
gram using the equation PWV=Δx/Δt, where Δx is differ-
ence in distance between the two sites relative to the
sternal notch, and Δt is the time for the wave to travel that
distance (the difference in time lapse from R-wave peak to
pressure wave peak, between the two sites). A minimum
of 2 measurements were used to calculate average PWV.
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Figure 1 Noninvasive assessments of vascular function in nonhuman primates(NHPs). A: FMD measurement in NHPs. A study protocol
diagram is shown in panel A. Primates were sedated, and PWV was measured first, followed by baseline femoral diameter measurement (D0).
Following a 5-min ischemia, the reactive hyperemia response was triggered by cuff release, and vessel diameter was measured at 1 min of the
hyperemia response (D1). Following a recovery from 1
st FMD determination, additional drug treatment and 2nd FMD measurement may apply if
needed, and this is typically achieved within 40 min. FMD is calculated as percentage change of D1 from D0. An ultrasonographic picture is
shown that depicts a femoral artery. B: PWV measurement in NHPs. Pulse waves from the right brachial and femoral arteries, as depicted, were
collected. PWV was calculated as the Distance/Time using the equation shown, which is based on distance difference (Δx) between the two
detection sites (femoral artery and brachial artery) and Δt, the difference in time lapse of a pressure wave gated to the corresponding ECG R-
wave at the two detection sites (B left panel). A window of PWV recording by SphygmoCor program is shown (B right panel). See Method part
for detailed description.
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femoral artery measurements were taken mid-thigh for
PWV. The average distal distance (femoral to notch) was
338 ± 5.4 mm and average proximal distance (brachial to
notch) was 75 ± 3.1 mm (n = 25). The distal vs. proximal
distance allowed sufficient difference to calculate the
PWV. Average detection variation for PWV was 10.6%.
FMD in the NHPs was measured using ultrasonog-
raphy, as illustrated in the Figure 1A. The right leg was
positioned and gently restrained to prevent movement
during the study. An infant V-Lok cuff (WA Baum,Copiague, NY) was then placed below the knee and
connected to a manometer. After applying ultrasonic
gel, a linear array probe (6–15 MHz), connected to a
Hewlett Packard Sonos® 5500 and mounted on an articu-
lated arm (PPM100, Tektronix, Inc. Beaverton, OR), was
positioned over the femoral artery, manipulated until a
clear signal was obtained and then locked in place for the
remainder of the protocol. Once a baseline recording of
the femoral artery was collected, the cuff was inflated
within 2 s to a super-systolic pressure (290-300 mmHg).
After 5 min the cuff pressure was rapidly released (<1 sec.)
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reperfusion approximating the time of maximal flow
mediated dilation [16]. Vessel diameter was measured,
using electronic calipers, for baseline and 1 minute re-
cordings. The average baseline femoral artery diameter
for the study colony was 0.151 ± 0.03 cm (n = 25). Flow
mediated dilation was calculated as the% change from
baseline diameter. Each diameter measurement was the
average of 4 segmental measurements taken ~1 mm
apart gated to the ECG T wave. At the end of the experi-
ment, monkeys were recovered by naloxone (0.05 mg/kg
im and 0.05 mg/kg iv – if they received butorphanol)
and flumazenil (2 mL per monkey, iv). FMD conducted
15 min apart showed average variation <5.5%.
Study design
Six fasted monkeys (17 ± 1 years of age) were treated orally
with both vehicle and rosiglitazone (1 mg/kg, coated on
one PrimaTreat; Bio-Serv, Frenchtown, NJ) ≥2 weeks apart
in a 2 × 2 crossover design (2 in vehicle-drug sequence and
4 in drug-vehicle sequence). Drug or vehicle was adminis-
tered at 6:00 AM, and, FMD and PWV were measured ~
six hours later, a time point that showed increased FMD in
a human study [12]. Blood samples were collected (via
cephalic vein) just prior to sedation, and immediately
processed for determination of endothelial microparticle,
endothelial progenitor cell and TNFα (detailed in following
methods). These treatments were repeated in the same ani-
mals to determine the effect of rosiglitazone on lipids and
intravenous glucose tolerance test.
A separate group of monkeys (n = 3, 15 ± 4 years of age)
were sedated, and intravenously infused with saline vehicle,
then with 0.844 μg/kg/min nicotine bitartrate (Sigma Al-
drich, St. Louis, MO), at rate of 0.4 mL/min. FMD was
recorded at 5 min of vehicle infusion, and at 15 min of
nicotine infusion (while the nicotine infusion was con-
stantly maintained), and the study was completed within 35
min. The nicotine dose used was calculated to approximate
the predicted blood nicotine concentration (40 nM) of a
human study in which chewing nicotine gum reduced
FMD [26,27].
Endothelial microparticle (EMP) and endothelial
progenitor cell (EPC) sample preparation and analysis
To measure EPC, whole blood was collected into EDTA
tubes from animals fasted overnight and, incubated with
anti-human CD34, CD31, CD45 (Becton Dickinson and
Co./BD, Franklin Lakes, NJ) and VEGFR2 (R&D Systems;
Minneapolis, MN.) antibodies. After lysing the red blood
cells, the samples were analyzed using a high performance
Canto II flow cytometer (BD) with DIVA software (BD).
At the same time, whole blood was collected in sodium
citrate tubes and platelet poor plasma (PPP) was prepared
to measure EMPs. An aliquot of PPP was added to each ofthe two panels of antibodies: Panel 1 [CD42a-APC (conju-
gated in house), CD31-FITC, CD45-AF700, Annexin V-
V450, CD105-PerCP (BD), CD54-PE (Invitrogen)]; Panel 2
[CD42a-APC (conjugated in house), CD31-FITC, CD45-
AF700, CD106-PE-Cy7 (conjugated in house), CD62E-PE
(BD), VEGFR2-PerCP (R&D Systems), CD144-Pacific Blue
(conjugated in house) (BioLegend, San Diego, CA.)]. Cytofix
was then added and a 500 uL aliquot was transferred into a
Trucount tube (BD) and analyzed by flow cytometry.
Biochemical tests and cytokine determination
Venous blood samples were collected in serum separator
tubes from untreated, rosiglitazone treated or vehicle
treated monkeys fasted overnight, centrifuged at 3000 rpm
for 10 min at 4°C, and levels of lipids and glucose mea-
sured on Siemens Advia 2400 chemistry analyzer, and
levels of insulin measured on the Siemens Centaur Im-
munoassay, with kits of Advia Chemistry Systems (Siemens
Healthcare Diagnostics Inc., Tarrytown, NY).
Lipopolysaccharide (LPS, Sigma-Aldrich) stimulated
release of TNFα was carried out, ex vivo, using sodium
heparin anti-clotted whole blood that was harvested
6 hours after rosiglitazone dosing. Blood was stimu-
lated with 10 ng/mL LPS for six hours with gentle
rocking, plasma separated by 14,000 rpm centrifu-
gation for 20 min at 10-15°C, and TNFα measured by
using Linco Luminex®mouse cytokine assay(EMD
Millipore, Billerica, MA).
Intravenous glucose tolerance test (IVGTT)
Monkeys fasted overnight were sedated with ketamine for
duration of IVGTT. Two iv catheters were placed for blood
sampling and glucose administration, respectively. Baseline
samples were drawn starting approximately 10 min after
initial ketamine dose and catheter placement. A 50% dex-
trose solution was then administered, iv, at 250 mg/kg over
20 s. Blood samples (~1 mL) for glucose and insulin ana-
lysis were collected in serum tubes at 2, 5, 7, 10, 15, 20 and
30 min post dextrose administration, centrifuged and the
resulting serum analyzed for glucose/insulin levels. The
Area Under the Curve (AUC) for plasma glucose and insu-
lin levels from 0 to 30 min was calculated. Glucose dis-
appearance rate was expressed as Kglc, the reduction of
the loge of plasma glucose levels between 5 & 20 min fol-
lowing iv glucose administration and calculated using the
formula: Kglc = (logeG1 – logeG2)/(t2 – t1) where G1 and
G2 are the glucose levels at time 5 min (t1) and 20 min
(t2) [28].
Statistical analysis
Pearson correlation coefficient was computed for correl-
ation study. Linear regression models were applied to in-
vestigate the relationships of age with FMD and PWV and
the relationship between FMD and PWV. In order to
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points of interest (FMD and PWV) compared to vehicle, a
linear mixed effect model was applied to analyze each of
the two endpoints from this 2 × 2 crossover study with age
adjustment. Specifically, the model has treatment (drug vs.
vehicle), sequence (1 vs. 2), and period (1 vs. 2) as fixed ef-
fects, age as a covariate, and subject (monkey) as random
effect. Paired t test was used to compare EMPs/EPCs pre-
and post- rosiglitazone treatment. Paired t test was applied
to analyze the FMD data measured in the nicotine infusion
study to evaluate the effect of nicotine on FMD compared
to saline vehicle. Results are presented as parameter esti-
mate (Mean) ± SEM. A two-sided p < 0.05 was considered
statistically significant.
Results
Age correlates to FMD and PWV in NHPs
To examine age effects on FMD and PWV in NHPs, we































Figure 2 Age correlates to FMD and PWV in NHPs. Age strongly correlat
p < 0.002, n = 23). FMD negatively correlates with PWV (C: r = -0.584, p < 0.002, n
poor positional signal and one that was (low) out of range.(Figure 1). FMD was measured in a colony of metabolically
healthy monkeys (n = 25) with age ranging from 6-26 years.
Serum levels of lipids (total cholesterol, HDL, LDL, and tri-
glycerides; Additional file 1: Table S1A) showed no indica-
tion of hyperlipidemia, and levels of blood urea nitrogen
and creatinine were normal indicating normal renal func-
tion. Since cynomolgus monkeys can naturally become
glucose intolerant the primates were assessed using an
IVGTT. Fasted blood glucose levels were normal and the
areas under the curve for glucose and the disappearance of
glucose in response to dextrose challenge were also nor-
mal, indicating no glucose intolerance in these monkeys
(Additional file 1: Table S1B).
In these metabolically healthy monkeys, FMD demon-
strated a robust dynamic range (6 to 33%) that cor-
related negatively with age (r = -0.892, p < 0.0001;
regression equation: y(%FMD) = -1.119x(year) + 36.00)
(Figure 2A). These data indicate that age has a signifi-
cant impact on FMD in NHPs. In the same monkeys,20 30
y=-1.119x+36.00
ar)















es with FMD (A: r = -0.892, p < 0.0001 n = 25) and with PWV (B: r = 0.622,
= 23). Two monkeys were excluded from the PWV analysis: one with a
Knight et al. Journal of Translational Medicine 2013, 11:101 Page 6 of 10
http://www.translational-medicine.com/content/11/1/101PWV ranged from 3 to 7 m/s, and also correlated with
age (r = 0.622, p < 0.002; regression equation: y(PWV) =
0.0917x(year) + 3.276) (Figure 2B). The reduction in
FMD also correlated with increase in PWV(r = -0.584,
p < 0.002) (Figure 2C). However, unlike FMD and PWV,
age did not significantly correlate with numbers of EPCs
or subsets of EMPs in these monkeys (Additional file 2:
Table S2).
Rosiglitazone improved, while nicotine impaired, FMD in
metabolically healthy monkeys
Using senescent monkeys, we examined the effect of
rosiglitazone on FMD. The FMD was significantly in-
creased following a single oral dose of rosiglitazone (21.0 ±
1.6% vs. vehicle 16.3 ± 1.6%) (Figure 3). Rosiglitazone treat-
ment had no effect on baseline femoral artery diameter
(1.52 ± 0.04 vs.1.51 ± 0.04 mm, respectively), and did not
affect PWV (Additional file 3: Figure S1) when compared
to vehicle treatment. In addition, when compared to ve-
hicle treatment, this dose of rosiglitazone had no signifi-
cant metabolic effects on baseline glucose, insulin, lipids,
IVGTT responses, or anti-inflammatory effects, as indi-
cated by the lack of LPS-stimulated TNFα release in these
























Figure 3 Acute treatment of rosiglitazone (panel A, study protocol, se
were adjusted by age. n = 6; **: p < 0.01.However, rosiglitazone treatment significantly increased
EPCs (CD45-CD31 + CD34 +VEGFR2+ 7.1 ± 1.3 vs. 4.8 ±
1.1 counts/μl) and reduced EMPs (CD45- CD42a- CD54+
26.7 ± 11.1 vs. 62.2 ± 9.8 counts/μl) (Additional file 3:
Figure S2). CD45- CD42a- CD105 + EMPs (16.5 ± 3.7 vs.
33.2 ± 5.6 counts/μl, n = 5, p = 0.06) and CD45- CD42a-
CD144+ EMPs (5.0 ± 1.5 vs. 41.8 ± 17.6 counts/μl, n = 5,
p = 0.09) also trended lower.
We next examined whether the deleterious effect of
nicotine on FMD can be detected in NHPs. Intravenous
infusion of nicotine in healthy monkeys significantly re-
duced FMD (8.7 ± 1.4% vs. vehicle 20.1 ± 2.2%) (Figure 4).
The plasma level of nicotine, at the time of FMD meas-
urement, was ~27 nM.
Discussion
Non-invasive measurement of vascular function in NHPs
We established a non-invasive method for FMD to
examine the effects of age on vascular function in NHPs.
Our protocol to measure FMD in NHP was adapted
from human protocols [1,7,29,30] and as such, FMD was
measured following a hyperemic response triggered by
distal limb ischemia. An important aspect of the present
technique was the use of a combination of anesthetics**
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Figure 4 Nicotine infusion (panel A, study protocol, see Methods for details) impairs FMD in NHPs (panel B). n = 3; *: p < 0.05.
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muscle relaxed without limb movement that was not ob-
served with ketamine alone. Measuring FMD using the
articulating arm also obviates the need to manipulate
the probe while measuring vascular diameter. These re-
finements were key in allowing us to detect a dynamic
range of changes in FMD associated with age and phar-
macological interventions in NHPs.
Age and FMD
Previously, total peripheral resistance was shown to fall
less with acetylcholine infusion in 19.8 ± 0.6 years old
monkeys than in 7.1 ± 0.4 years old monkeys [31],
suggesting an age-related impairment of vascular dilatory
response to acetylcholine. Since NHP can live as adults for
decades, a better understanding of the relationship be-
tween age and FMD/PWV would be important in order to
avoid the confounding effects of age. Here, we examined
the age effect on the flow-induced vascular dilatory re-
sponse in a colony of adult, sexually mature monkeys, 6
to 26-years of age. The robust age-FMD relationship
(Figure 2A) has at least three implications. (i) The age-
dependent nature of FMD recapitulates that seen in hu-
man [6], suggesting a translational feature of NHP model
of FMD. (ii) For studies evaluating the effects of test
agents on FMD in NHPs, prior randomization by age and/
or recording of age at baseline is necessary, and age-
dependent vs. disease-ameliorating effects on FMD may
also need to be considered to clarify mechanisms of ac-
tion. (iii) Prior vascular health assessment by FMD can be
used to select NHPs most likely affected by test agents.This is particularly important for selecting study subjects
from a heterogeneous population of NHPs. For example,
monkeys develop diabetes and metabolic syndrome at var-
ied age [16,17], and diabetes itself features endothelial dys-
function (reduced FMD) in human [32]. In addition, the
age-FMD relationship allows us to put in perspective the
effect of test agents on vascular function (FMD). It is in-
teresting to note that the average improvement in FMD
following rosiglitazone treatment (Figure 3) was equivalent
to improving the monkeys’ vascular age by 5.2 years.
PWV also correlates with age in NHPs (Figure 2), indi-
cating that, similar to the FMD assessment, age effect
should also be considered when evaluating PWV, by
prior randomization of study groups or by age adjust-
ment. Furthermore, age-adjustment decreases variation
in FMD and PWV by 79.57% and 38.67%, respectively,
among these NHPs. This suggests a stronger age impact
on FMD than PWV.
Evaluation of FMD changes in NHPs
We established that the non-invasive methodology can
be used to assess beneficial (rosiglitazone) and detrimen-
tal (nicotine) FMD changes following drug intervention
in NHPs (Figures 3 and 4). Chronic treatment of diabetic
patients with rosiglitazone ameliorates insulin resistance
and its related metabolic disorder while improving FMD
[11]. Acute treatment also results in FMD improvement
in healthy subjects in the absence of associated meta-
bolic effects [12]. In line with these earlier studies, we
reported here that rosiglitazone improved FMD in meta-
bolically healthy NHPs (Figure 3), without drug-related
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Table S3). In a recent study [16] using NHPs of similar
age to those studied here, 6-week pioglitazone treatment
improves metabolic parameters, and reverses the im-
paired FMD that co-emerged with the metabolic syn-
drome. In senescent euglycemic monkeys, our results
show that rosiglitazone caused an acute improvement in
FMD that was independent of effects on cytokine (TNFα)
release or metabolic effects on glucose and lipids. This
suggests that PPARγ agonists may have a direct action on
the endothelium in vivo beyond its systemic metabolic
effects.
Despite the lack of age-related correlation of EPCs and
any of the EMPs, acute treatment with rosiglitazone de-
creased the number of EMP(CD45-CD42a-CD54+) and in-
creased EPC(CD45-CD31 +CD34 +VEGFR2+) (Additional
file 3: Figure S2). CD54(ICAM-1) is an intercellular adhe-
sion molecule expressed on endothelial cells, and is associ-
ated with increased cell activation [33]. Although somewhat
controversial, EPCs are believed to play an important role
in the endogenous repair mechanisms for maintaining the
integrity of the endothelial monolayer [34,35]. PPARγ is
known to regulate endothelial survival and function [22,23],
as well as, EPC function [24,25]. The rosiglitazone induced
increase in FMD coincided with acute increases in EPCs
and suppression of EMPs suggesting an improvement in
endothelial health. While these changes in EPCs and EMPs
do not provide a causal, mechanistic link for the FMD
changes, from a drug discovery view point, our results
could provide the impetus for further studies to evaluate
the use of EPCs/EMPs as biomarkers to potentially capture
a signal of vasculature change of test drugs.
Cigarette smoking is associated with impairment of
FMD [1,36,37], and treatment with nicotine gum attenu-
ates FMD in human subjects [26]. In this study, the
plasma levels of infused nicotine(~27 nM), at the time of
FMD measurement, matched to the levels in humans
that are associated with reduced FMD [37], and also ap-
proximated the nicotine level (~40 nM) predicted from
another human study, in which nicotine gum treatment
reduces FMD [26]. Nicotine’s effect on the cardiovascu-
lar system is complex [38], including release of pro-
inflammatory mediators, thrombosis, decreasing oxygen
supply, and increasing sympathetic nerve activity [39].
The significant reductions in FMD with nicotine further
support the translation of this model to clinical out-
comes and illustrates how robust this preclinical, NHP
model is in detecting changes in FMD (only 3 animals
required) in a highly controlled laboratory setting.
Unlike other models [40], the NHP is considered as a
highly translational animal model of cardiovascular
disease [13], and is often used as a preclinical model to
evaluate therapeutic agents. This translation is also
supported by the observed correlation between age andFMD/PWV in this study. NHPs are phylogenetically
closer to humans, and may be particularly useful when
a drug target does not exist in other species (for ex-
ample, Cholesteryl ester transfer protein, a regulator of
HDL levels, is not present in rodents). The non-
invasive nature of FMD allows reuse of animals for
cross-over and longitudinal studies. Further, the phar-
macological effects on FMD might be detected with a
relatively small group of animals (for example, 6 mon-
keys were used in the rosiglitazone study) under a
well-controlled environment that is difficult to dupli-
cate in clinical studies. The described FMD method-
ology using NHPs, might be highly valuable both for
translational research, drug efficacy/safety evaluation,
and for clinical dose-selection. This is particularly im-
portant for developing diabetes drugs. New guidelines
of FDA require cardiovascular safety assessment before
approval of any diabetes drugs [41].Study limitations
Blood flow was not assessed during these FMD determi-
nations. FMD measured under our current protocol does
not distinguish between macro- and micro-circulation
effects; rather, it serves as an integrated assessment of
vascular endothelium function. The variability of PWV
detection under current protocol needs to be optimized,
which may limit the power to detect a biological impact.
Detection of EMPs and EPCs may have been limited by
the availability of antibodies and the degree of cross-
species reactivity of the human antibodies with monkey.
As they become available, the use of additional anti-
bodies for EMP/EPC markers and their functional
characterization could provide further insight and utility
in assessing vascular health.Conclusions
In conclusion, we established a non-invasive, clinically-
relevant approach to assess vascular function in NHP by
measuring FMD and PWV, and identified age as a sig-
nificant modifier of FMD, and to a less degree, of PWV.
Acute treatment with rosiglitazone improves FMD, while
nicotine reduces FMD in senescent primates. Senescent
primates with age-related endothelial dysfunction may
provide a unique model for evaluating preclinically the
efficacy and safety of therapeutic agents on endothelial
function (i.e. FMD). The endothelial function assessment
with FMD in NHPs and the associated circulating bio-
markers (i.e. EPC, EMP), as described herein, may serve
as a novel approach for translational research and thera-
peutic discovery. Like in humans, age is an important
confounder that should be considered when assessing
cardiovascular health and interpreting drug actions in
NHPs.
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Additional file 1: Table S1. Basal metabolic parameters of the study
monkeys. A: Blood lipids profile. B: Glucose, insulin, and IVGTT.
Additional file 2: Table S2. FMD or age does not correlate with
numbers of EPCs or EMPs in metabolically healthy monkeys. n = 19 and
21 for EPC and EMP, respectively.
Additional file 3: Figure S1. Rosiglitazone does not affect PWV in
NHPs. n = 6, p = 0.22 (age adjusted). NS: non-significant. Figure S2.
Rosiglitazone results in favorable changes in circulating numbers of EMPs
(CD45-CD42a-CD54+) (A) and EPCs (CD45-CD31 + CD34 + VEGFR2+) (B) in
euglycemic, senescent monkeys. n = 5, *: p < 0.05; **: p < 0.01.
Additional file 4: Table S3. Effect of rosiglitazone treatment on blood
biochemistry and LPS-stimulated TNFα release. No significant difference
between the two groups, n = 5 (vehicle) or 6 (rosiglitazone). Kglc, 5-20:
slope of the disappearance of glucose 5-20 min after dosing; AUC0-30:
area under the curve for glucose or insulin (0-30 min).
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